The Reference Compound for GLP Research
When new GLP-class compounds are published, their effect size is almost always reported relative to semaglutide. That makes semaglutide the practical reference point for the entire class — and the starting point for most receptor-comparison research.
For comparison studies, GLP-1 S 10mg Semaglutide is the standard research format.
The C18 Fatty Acid Modification
Native GLP-1 has a half-life measured in minutes. Semaglutide extends this to approximately 7 days through a C18 fatty diacid side chain attached via a short linker. The fatty acid binds circulating albumin, which:
- Shields the peptide from DPP-IV cleavage
- Reduces renal clearance
- Provides a long-lived albumin-peptide complex that slowly releases active compound
The result is a research compound with once-weekly dosing kinetics — which in turn shapes protocol design.
STEP-1 Summary
The STEP-1 trial (NEJM 2021):
- Duration: 68 weeks
- Dose: 2.4mg/week maintenance
- Mean weight change: −14.9%
- Placebo-adjusted: −12.4 percentage points
This result established semaglutide as the effective ceiling for mono-receptor GLP-1R research until dual- and triple-receptor compounds extended the ceiling further.
Research Positioning
Semaglutide earns its research utility specifically through its mono-receptor profile — not despite it:
- Single-variable receptor research requires single-receptor engagement
- Dose-response studies at GLP-1R benefit from a compound with minimal off-target activity
- Comparative research against dual/triple agonists requires a validated mono-agonist baseline
Handling and Stability
Lyophilized semaglutide is stable at −20°C for 12+ months. Reconstituted solution at 2–8°C is typically used within 28 days. All research-grade semaglutide should carry >98% HPLC certification.
Research Window Design
Semaglutide's 7-day half-life means weekly dosing is protocol-native. Steady state is reached at approximately 4–5 weeks, so research windows need to account for this ramp-up period. Most protocols discard the first 4–6 weeks from primary analysis for this reason.
Start a semaglutide research protocol at GLP-1 S 10mg Semaglutide.